Nurix Therapeutics, Inc. (NRIX)

From the record

Nurix Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Nurix Therapeutics, Inc.'s 4 filed years say what it did: revenue went from $39 million in fiscal 2022 to $84 million in fiscal 2025, up 29.5% a year; it rose in 2 of 3 years; the deepest fall was 29% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 4 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-11-30, Nurix Therapeutics, Inc. lost about 49 cents for every dollar of shareholders' money. Leverage: it owed about 22 cents per dollar of assets, and net share issuance: its share count grew 29.1% over the year (the filed statements).

From the record

Nurix Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $84 million in fiscal 2025 ranks in the top 36% by size; a net margin of -314.9% ranks in the bottom 42%; revenue growth of 29.5% a year over the last 3 filed years ranks in the top 31% (its annual reports).

From the record

Nurix Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sands, Arthur T (President, CEO, as filed), filing under that title since 2020-07-23, 6.3 years (top 35% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (top 47%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Nurix Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $247 million against no long-term debt tagged leaves 35.9% of its assets as net cash, top 42% of its family; cash from operations less capital spending is -313.7% of revenue (bottom 40%); research spending of 377.4% of revenue (top 33%) (its annual report).

From the record

Nurix Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 29.5% a year over the last three filed years against 29.5% over all 4, speeding up (top 40% of its family); the newest year grew 54% (top 24%); research spending grew 19.8% a year (top 24%); capital spending grew 4.6% a year (top 34%) (its annual reports). Nurix Therapeutics, Inc. reported 2 product lines in fiscal 2025: Collaboration Revenue at $54 million (64%), License Revenue at $30 million (36%); 0 of 1 grew against the year before (its annual report).

From the record

Nurix Therapeutics, Inc.'s newest year against its own record: revenue of $84 million in fiscal 2025 came in 29.6% above the $65 million its prior three years' pace pointed to (top 24% of its family); net income of $264 million against a prior three-year average of $173 million (bottom 24%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 44%) (its annual reports).